Skip to main content
SpringerLink
Log in

Korreliert die Prävalenz der bisphosphonatassoziierten Kiefernekrosen mit der Einnahmedauer der Bisphosphonate bei Tumor- und Osteoporosepatienten?

Gesamtauswertung des Deutschen Kieferosteonekroseregisters

Correlating the prevalence of bisphosphonate-associated osteonecrosis of the jaw with the duration of onset of bisphosphonates in tumor and osteoporosis patients

Overall evaluation of the German osteonecrosis of the jaw registry

  • Originalien
  • Published:
Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen Aims and scope

Zusammenfassung

Die erste Veröffentlichung zum Thema der Osteonekrose des Kieferknochens (ONJ, „osteonecrosis of the jaw“) erfolgte 2003. Bei Tumor- und Osteoporosepatienten werden im Zuge ihrer Grunderkrankung Bisphosphonate appliziert. Dies geschieht bei Tumorpatienten zur Risikoreduktion der Entwicklung einer Knochenmetastasierung, bei Osteoporosepatienten zur Verringerung des Frakturrisikos. Trotz der geringen Wahrscheinlichkeit werden Nebenwirkungen in Form von Nekrosen nach Interventionen am Kieferknochen häufig von den behandelnden Ärzten erwartet. Nach Auswertung der Registerdaten konnte nicht festgestellt werden, dass die Länge der Einnahme mit der Prävalenz von ONJ korreliert. Die Lokalisationen der ONJ decken sich weitestgehend mit den Ergebnissen bisheriger Studien.

Abstract

The first description of osteonecrosis of the jaw (ONJ) was published in 2003. Bisphosphonates (BPs) have been used as antiresorptive agents to treat patients with osteoporosis or metastatic bone cancer. In patients with tumors and osteoporosis, bisphosphonates are applied as part of their underlying disease. Bisphosphonates are used in tumor patients to reduce the risk of developing bone metastases and in osteoporotic patients to reduce fracture risk. Despite the low likelihood, side effects in the form of necrosis after interventions on the jawbone are often expected by the treating physicians. After evaluating the registry data, it could not be determined that the length of intake correlated with the prevalence of ONJ. The localizations of the ONJ coincide with the results of recent studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7
Abb. 8
Abb. 9
Abb. 10
Abb. 11
Abb. 12
Abb. 13
Abb. 14
Abb. 15
Abb. 16
Abb. 17
Abb. 18

Literatur

Verwendete Literatur

  1. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117

    Article  PubMed  Google Scholar 

  2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534

    Article  PubMed  Google Scholar 

  3. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ) (2004) Osteonekrose des Kiefers unter Bisphosphonaten. Dtsch Arztebl 101:A2203

  4. Freyschmidt J (1980) Knochenerkrankungen im Erwachsenenalter. Springer, Berlin

    Book  Google Scholar 

  5. Akintoye SO, Lam T, Shi S et al (2006) Skeletal sitespecific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. Bone 38:758–768

    Article  CAS  PubMed  Google Scholar 

  6. Stefanik D, Sann J, Lam T et al (2008) Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis 14:465–471

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, D’Aleo P, Corradi D, Corcione L, Sesenna E, Ferrari S, Poli T, Bonaninil M, Vescovi P (2006) Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 77(2):109–117

    CAS  PubMed  Google Scholar 

  8. Re M, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575

    Article  Google Scholar 

  9. Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97(12):2692–2696

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222–6230

    Article  Google Scholar 

  11. Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (2008) Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42:848–860

    Article  CAS  PubMed  Google Scholar 

  12. Bartl R, von Tresckow E, Bartl C (2006) Bisphosphonat Manual. Springer, Berlin, Heidelberg, New York, S 43–93. ISBN 3‑540-25362‑9

    Book  Google Scholar 

  13. Yamaguchi A, Kubo S, Matsunaga T, Shibahara T (2018) Report by the jaw bone disease project 1: concept, diagnosis and treatment of medication-related osteonecrosis of the jaw. Shikwa Gakuho 118:165–176

    Google Scholar 

  14. Fleisch H (2002) The role of bisphosphonates in breast cancer: development of bisphosphonates. Breast Cancer Res 4(1):30–34

    Article  CAS  PubMed  Google Scholar 

  15. Mutschler E, Geisslinger G, Kroemer HK, Schäfer-Korting M (2001) Mutschler Arnzeimittelwirkungen, 8. Aufl. Wissenschaftliche Vertragsgesellschaft, Stuttgart, S 395–398

    Google Scholar 

  16. International Task Force on Osteonecrosis of the Jaw (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:1

    Article  Google Scholar 

  17. Aspenberg P (2006) Osteonecrosis: what does ist mean? One condition partly caused by bisphosphonates—or another one, preferably treated with them? Acta Orthop 77(5):693–694

    Article  PubMed  Google Scholar 

  18. Allen MR, Ruggiero SL (2009) Higher bone matrix density exists in only subset of patients with bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 67:1373–1377

    Article  PubMed  Google Scholar 

  19. Sharma D, Ivanovski S, Slevin M et al (2013) Bisphosphonate-related osteonecrosis of the jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vasc Cell 5:1–5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Fedele S, Porter SR, D’Aiuto F et al (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123:1060–1064

    Article  CAS  PubMed  Google Scholar 

  21. Ruggiero SL, Fantasia J, Carlson E (2006) Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:433–441

    Article  PubMed  Google Scholar 

  22. Fournier P, Boissier S, Filleur S et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544

    CAS  PubMed  Google Scholar 

  23. Santini D, Vincenzi B, Dicuonzo G et al (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893–2897

    CAS  PubMed  Google Scholar 

  24. Vincenzi B, Santini B, Dicuonzo G et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144–151

    Article  CAS  PubMed  Google Scholar 

  25. Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587. https://doi.org/10.1200/JCO.2005.02.8670

    Article  PubMed  Google Scholar 

  26. Cartsos VM, Zhu S, Zavras A (2008) Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714.217 people. Am Dent Assoc 139:23–30

    Article  Google Scholar 

  27. Lo JC, O’Ryan FS, Gordon NP et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonates exposure. Oral Maxillofac Surg 68:243–253

    Article  Google Scholar 

  28. Felsenberg D (2006) Osteonecrosis of the jaw—a potential adverse effect of bisphosphonate treatment. Nat Clin Pract Endocrinol Metab 2:2662–2663

    Article  Google Scholar 

  29. Khan AA et al (2011) Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 38:1396–1402

    Article  CAS  PubMed  Google Scholar 

  30. Lyles KW et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809

    Article  CAS  PubMed  Google Scholar 

  31. Powell D, Bowler C, Roberts T et al (2012) Incidence of serious side effects with intravenous bisphosphonates: a clinical audit. QJM 105:965–971

    Article  CAS  PubMed  Google Scholar 

  32. Tennis P, Rothman KJ, Bohn RL et al (2012) Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 21:810–817

    Article  CAS  PubMed  Google Scholar 

  33. Grbic JT, Landesberg R, Lin SQ et al (2008) Incidence of osteonecrosis of the jaw in women with postmenosaumal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 139:32–40

    Article  CAS  PubMed  Google Scholar 

  34. Devogelaer JP, Brown JP, Burckhardt P et al (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18:1211–1218

    Article  CAS  PubMed  Google Scholar 

  35. Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L (2008) Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leukemia Lymphoma 49(11):2156–2162

    CAS  Google Scholar 

  36. Klingelhoeffer Ch, Hoffmeister B (2012) Klinische Aspekte der Behandlung von Kiefernekrosen unter antiresorptiver Therapie. Osteologie 3:201–206

    Google Scholar 

  37. Ferlito S, Puzzo S, Liardo C (2011) Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. J Oral Maxillofac Surg 69(6):e1–e4

    Article  PubMed  Google Scholar 

  38. Ripamonti CI et al (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145

    Article  CAS  PubMed  Google Scholar 

  39. Dimopoulos MA et al (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–120

    Article  CAS  PubMed  Google Scholar 

  40. Haidar A et al (2009) Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw. Scand J Urol Nephrol 43:442–444

    Article  CAS  PubMed  Google Scholar 

  41. Fehm T, Walter B, Wallwiener D (2010) Bisphosphonatbedingte Kieferosteonekrose. Empfehlungen zur Prävention und Therapie. Gynäkologe 43:517–520

    Article  Google Scholar 

  42. Ruggiero SL, Dodson TB, Assael LA et al (2009) Task force on bisphosphonate-related osteonecrosis of the jaws. Am Assoc Oral Maxillofac Surg 69:2–12

    Google Scholar 

  43. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, Krikelis D, Terpos E (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134:620–623

    Article  CAS  PubMed  Google Scholar 

  44. Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21:1545

    Article  CAS  PubMed  Google Scholar 

  45. Wessel JH, Dodson TB, Zavras AI (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66:625–631

    Article  PubMed  PubMed Central  Google Scholar 

  46. Chranovic BR, Albrektsson T, Wennerberg A (2015) Smoking and dental implants: a systematic review and meta-analysis. J Dent 43:487–498

    Article  Google Scholar 

  47. Shanbhogue VV, Mitchell DM, Rosen CJ et al (2016) Type2 diabetes and the skeleton: new insights into sweet bones. Lancet Diabetes Endocrinol 4:159–173

    Article  CAS  PubMed  Google Scholar 

  48. Yahagi K, Kolodgie FD, Lutter C et al (2017) Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arter Thromb Vasc Biol 37:191–204

    Article  CAS  Google Scholar 

  49. Hua Y, Bi R, Zhang Y et al (2018) Different bone sites-specific response to diabetes rat models: bone density, histology and microarchitecture. PLoS ONE 13:e205503

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Vahtsevanos K et al (2009) Longitudinal cohortstudy of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362

    Article  CAS  PubMed  Google Scholar 

  51. Felsenberg D, Lopez S, Gabbert T, Hoffmeister B (2012) Osteonekrose des Kiefers bei Osteoporosepatienten. Onkologie 3:207–212

    Google Scholar 

  52. Felsenberg D, Hoffmeister B, Amling M et al (2006) Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch Zahnärztebl 103:3078–3080

    Google Scholar 

  53. Shibahara T (2019) Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): a twist of fate in the bone. Tohoku J Exp Med 247(2):75–86

    Article  PubMed  Google Scholar 

  54. Vandone AM et al (2012) Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 23:193–200

    Article  CAS  PubMed  Google Scholar 

  55. De Iuliis F, Taglieri L, Amoroso L, Vendittozzi S, Blasi L, Salerno G, Lanza R, Scarpa S (2014) Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. Anticancer Research 34:2477–2480

    Google Scholar 

  56. Bramati A, Girelli S, Farina G, Chiara M et al (2015) Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab 33:119–124

    Article  CAS  PubMed  Google Scholar 

Weiterführende Literatur

  1. Horn F (2015) Biochemie des Menschen. Thieme, Stuttgart, New York

    Book  Google Scholar 

  2. Gilman’s G (2011) The pharmacological basis of therapeutics Bd. 12. Mc Graw Hill Medical, New York, Chicago, San Francisco

    Google Scholar 

  3. Rogers TL, Holen I (2011) Tumour macrophages as potential targets of bisphosphonates. J Transl Med 9:177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Diel I (2012) Kieferosteonekrosen in der Osteoonkologie. Osteolgie 3:194–200

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Danube Private University, Steiner Landstraße 124, 3500, Krems-Stein, Österreich

    Niels Karberg BA

  2. Charité – Universitätsmedizin Berlin, Berlin, Deutschland

    Dieter Felsenberg

Authors
  1. Niels Karberg BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dieter Felsenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Niels Karberg BA.

Ethics declarations

Interessenkonflikt

N. Karberg und D. Felsenberg geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karberg, N., Felsenberg, D. Korreliert die Prävalenz der bisphosphonatassoziierten Kiefernekrosen mit der Einnahmedauer der Bisphosphonate bei Tumor- und Osteoporosepatienten?. J. Miner. Stoffwechs. Muskuloskelet. Erkrank. 27, 8–18 (2020). https://doi.org/10.1007/s41970-019-00094-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s41970-019-00094-6

Schlüsselwörter

Keywords

Search

Navigation